Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function.

Although S1P receptor modulator–treated patients composed a smaller cohort, we observed a nonsignificant trend between longer cumulative duration of S1P receptor modulator therapy and lower total spike and spike RBD IgG levels ( Figure 1, I and J ).

also in 5,406 other papers